Levetiracetam for Status Epilepticus

Introduction to Levetiracetam Use

The American Academy of Emergency Medicine recommends levetiracetam as a second-line agent for status epilepticus refractory to benzodiazepines, with efficacy comparable to valproate (73% vs 68% seizure cessation) 1, 2

For status epilepticus, a loading dose of 30 mg/kg IV at 5 mg/kg/minute is recommended 1, 2
Alternative dosing studied includes 1500-2500 mg IV over 5 minutes 1, 2
Lower doses (20 mg/kg) show reduced efficacy (38% within 30 minutes) 1, 2
For ED loading in known seizure patients, 1500 mg oral or rapid IV loading (up to 60 mg/kg has been well tolerated) is suggested 3

Studies show 44-73% efficacy when used after benzodiazepine failure 1, 2
Levetiracetam has similar efficacy to valproate when both used at 30 mg/kg IV 1, 2
Adverse effects are minimal, including fatigue, dizziness, rarely nausea or transient transaminitis 1, 2

While effective as second-line for status epilepticus, evidence for use as third-line (after benzodiazepines AND phenytoin/valproate) is less clear 1, 2

La dosis de 1500-2500 mg IV administrados en 5-15 minutos ha sido efectiva en pacientes ancianos, con una reducción del 89% en las crisis y una cesación completa del 78% 4
Dosis más bajas de 20 mg/kg muestran eficacia reducida, del 38-67%, y no se recomiendan como primera opción 4

No se documentaron eventos adversos graves en las series de casos revisadas, con efectos adversos que incluyen fatiga, mareos, raramente náusea o transaminitis transitoria 4

La dosis de mantenimiento de 500-1500 mg cada 12 horas se basa en la respuesta clínica, según la evidencia disponible 4

Patients receiving Levetiracetam IV should be monitored for at least 2 hours after administration, with vital signs and neurological assessments performed every 15 minutes during infusion and for 2 hours post-infusion, then every 30 minutes for 6 hours, then hourly until 24 hours, as recommended by the American Heart Association, based on acute neurological intervention guidelines and the pharmacokinetic profile of levetiracetam 5
Perform neurological assessments every 15 minutes during the infusion and for the first 2 hours after completion, focusing on seizure activity or recurrence, as per the guidelines for acute neurological intervention 5
Monitor vital signs every 15 minutes during this critical period, including blood pressure, as recommended by the American Heart Association 5

Every 30 minutes for hours 2-8: Continue vital signs and neurological checks, as per the guidelines for monitoring after levetiracetam administration 5
Hourly from 8-24 hours: Maintain surveillance for delayed adverse effects, such as somnolence and sedation, as recommended by the American Academy of Neurology 5

The 2-hour minimum monitoring period is based on stroke thrombolytic protocols which provide the most rigorous neurological monitoring framework available, as recommended by the American Heart Association 5